Advanced search
Start date

Evaluation of liquid-crystalline nanodispersions potential functionalized with cetuximab for the incorporation of docetaxel in the treatment of prostate cancer

Grant number: 16/22042-5
Support type:Scholarships in Brazil - Master
Effective date (Start): June 01, 2017
Effective date (End): July 31, 2018
Field of knowledge:Health Sciences - Pharmacy - Pharmaceutical Technology
Cooperation agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
Principal Investigator:Marlus Chorilli
Grantee:Lucas Noboru Fatori Trevizan
Home Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil


Prostate cancer is the second most common cancer among men in Brazil and it is characterized by no presenting symptoms in early stages,for this reason it is diagnosed in advanced stage, which often complicates treatment. Some related factors enhance their aggressiveness, for example, overexpression of epidermal growth factor receptor (EGFR), in some subtypes of prostate tumors. In this respect, the inhibition of the EGFR helps fight against the cancer, this function relate to the chimeric IgG1 monoclonal antibody (cetuximab) which binds to the outer portion of EGFR, inhibiting cellular proliferation, metastasis and angiogenesis and promote apoptosis. Among the forms of treatment include the brachytherapy, radiotherapy and chemotherapy using docetaxel, which has survival advantage in patients with metastatic prostate cancer resistant to antiandrogen therapy. However, the commercial formulation has side effects such as, fever, anemia, water retention, hypersensitivities, myalgia, mucositis, peripheral neuropathies, and have toxicity to skin and nails. Thus, it is appropriate to search for alternative carriers to docetaxel, as the liquid-crystalline nanodispersions, which have high characteristics of biocompatibility and the possibility of sustained release, representing a promising alternative for the delivery of this drug. In this context, the nanostructure functionalization strategies with monoclonal antibodies, such as cetuximab, also has the benefit of allowing site-specific release of the encapsulated drug, with possible reduction of side effects. It should be considered that docetaxel acts in synergism with cetuximab, justifying the combination therapy. For this reason, this proposal aims is to evaluate the potential of liquid-crystal nanodispersions functionalized with cetuximab for the placement of docetaxel in the treatment of prostate cancer, with evaluation in models of PC-3 and DU145 cell lines (AU)

Academic Publications
(References retrieved automatically from State of São Paulo Research Institutions)
TREVIZAN, Lucas Noboru Fatori. Avaliação do potencial de nanodispersões de cristal líquido funcionalizadas com cetuximabe na veiculação de docetaxel para o tratamento do câncer de próstata. 2018. 92 f. Master's Dissertation - Universidade Estadual Paulista "Júlio de Mesquita Filho" Faculdade de Ciências Farmacêuticas..

Please report errors in scientific publications list by writing to: